Neuronetics (STIM) and Greenbrook TMS Announce Definitive Agreement to Merge
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Neuronetics (STIM) PT Lowered to $3 at Canaccord Genuity
August 13, 2024 6:23 AM EDTCanaccord Genuity analyst William Plovanic lowered the price target on Neuronetics (NASDAQ: STIM) to $3.00 (from $6.00) while maintaining a Buy rating.
The analyst comments "Bottom line: STIMs Q2/24 missed estimates with $16.5M of revenue, driven by low treatment session revenue as customers delayed refilling inventory due to continued prior authorization and reimbursement headwinds from Change Healthcares cybersecurity breach impacting STIMs customer base. That said, STIM reiterated its FY24 revenue guidance of $78M-$80M, displaying confidence in the... More
